Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Abroad (travel likely)RecruitingPHASE3

Conditions

Esophageal Squamous Cell Carcinoma · Oligometastatic Disease · Radiotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai cancer center, Shanghai, China
Contact: Study coordinator (Kuaile Zhao, MD) · kuaile_z@sina.com · 86-18017312534

Study leads

Kuaile Zhao, MD
Study Director
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Esophageal Carcinoma · Radiotherapy · Immunotherapy

Abroad (travel likely)RecruitingPHASE3

Shanghai, China

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Resectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Tumor Regression Grade As Predictor of Adjuvant Therapy

Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)Recruiting

Fuzhou, China

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Beijing, China